Latest Content

Jaypirca Matches Imbruvica's Effectiveness for CLL, With Hints of Long-Term Benefit

December 7th 2025, 7:58pm

By Jason M Broderick

Article

A clinical trial found that Jaypirca was more effective than Imbruvica across the frontline and relapsed/refractory CLL/SLL settings.

Epkinly Combo Effective in Second-Line R/R Follicular Lymphoma

December 7th 2025, 7:02pm

By Gina Mauro

Article

The phase 3 EPCORE FL-1 trial showed that adding Epkinly to Rituxan and Revlimid delivered superior PFS and response rates.

A New Option Without Traditional Chemotherapy for Ph+ ALL

December 7th 2025, 6:49pm

By Ariana Pelosci

Article

A new combination of Blincyto and Iclusig provided improved results and stronger responses for patients with Philadelphia chromosome-positive ALL compared with traditional chemotherapy.

Azacitidine Plus Venclexta Superior to Chemo in Acute AML

December 7th 2025, 5:47pm

By Jonah Feldman

Article

Among fit patients with acute myeloid leukemia, azacitidine plus Venclexta was shown to be superior to intensive chemotherapy.

Older Patients With DLBCL May Benefit From First-Line Epkinly Plus R-mini-CHOP

December 7th 2025, 4:45pm

By Kristie L. Kahl

Article

Among older patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), Epkinly plus R-mini-CHOP appeared to be well tolerated and elicited responses.

Higher Niktimvo Dosing Feasible in Chronic Graft-Versus-Host Disease

December 7th 2025, 3:19pm

By Kristie L. Kahl

Article

Transitioning treatment with Niktimvo to a dose of 0.6 mg/kg every four weeks appeared feasible for chronic graft-versus-host disease.

Black Patients With AML Face Lower Survival Outcomes

December 7th 2025, 2:40pm

By Bridget Hoyt

Article

Race has been identified as an independent prognostic factor in patients with AML receiving intensive chemotherapy.

KRd Improves Progression in Newly Diagnosed Patients With Myeloma

December 7th 2025, 12:35am

By Jax DiEugenio

Article

KRd improved progression-free survival, deepened responses, and led to higher MRD negativity versus VRd in patients with newly diagnosed multiple myeloma.

Real-Time Text Tool Tracks Quality of Life in Myeloma Care

December 7th 2025, 12:05am

By Dr. James Berenson

Video

Real-time text check-ins helped physicians identify issues sooner and support quality of life for patients with myeloma at ASH 2025.

Odronextamab Plus CHOP Shows Early Efficacy in DLBCL

December 6th 2025, 10:55pm

By Silas Inman

Article

Among patients with previously untreated diffuse large B-cell lymphoma, odronextamab has been associated with early efficacy.

Elrexfio Maintains Responses in Elderly, Frail Patients With Multiple Myeloma

December 6th 2025, 9:32pm

By Tim Cortese

Article

In patients with R/R multiple myeloma, real-world Elrexfio was associated with shorter time until progression but higher rates of response than Tecvayli.

Fixed Duration Venclexta Combos Delay Progression in CLL Similarly to Imbruvica

December 6th 2025, 8:13pm

By Gina Mauro

Article

Venclexta regimens showed comparable progression-free survival versus continuous Imbruvica.

Pediatric and AYA B-ALL Treatment Effective Without Total Body Irradiation

December 6th 2025, 5:46pm

By Ariana Pelosci

Article

For pediatric and young adult patients with B-cell acute lymphoblastic leukemia, removal of total body irradiation did not compromise efficacy.

Families of Children With ALL Face Catastrophic Financial Toxicity

December 6th 2025, 3:34pm

By Alex Biese

Article

Among children receiving chemotherapy for acute lymphoblastic leukemia, 30% of their families developed catastrophic financial toxicity.

First Annual Blood Cancer Heroes Honors Leaders, Advocates and Survivors

December 6th 2025, 1:44pm

By Spencer Feldman

Article

CURE honored four individuals whose compassion and leadership shaped support education and empowerment for people living with blood cancers.